Duration of response with PI3Kδ inhibitor INCB040093 alone or in combination with JAK1 inhibitor itacitinib, by lymphoma subtype (ITT)
| Tumor subtype . | Median DOR (95% CI), mo . | |
|---|---|---|
| Monotherapy (n = 21) . | Combination therapy (n = 28) . | |
| CLL/SLL | NR (13.9-NE) (n = 6) | — |
| WM | NR (NE-NE) (n = 1) | — |
| MCL | 9.7 (2.1-1 = 7.3) (n = 2) | — |
| FL | 7.6 (0.1-NE) (n = 5) | 11.3 (4.7-NE) (n = 4) |
| Nodal MZL | NR (NE-NE) (n = 1) | NR (NE-NE) (n = 1) |
| Splenic MZL | — | 6.1 (NE-NE) (n = 1) |
| DLBCL | NR (NE-NE) (n = 1) | NR (2.6-NE) (n = 6) |
| Transformed NHL | — | NR (NE-NE) (n = 1) |
| cHL | 8.9 (4.3-NE) (n = 5) | NR (2.6-NE) (n = 14) |
| PMBCL | — | — |
| NLP HL | — | 3.8 (NE-NE) (n = 1) |
| Tumor subtype . | Median DOR (95% CI), mo . | |
|---|---|---|
| Monotherapy (n = 21) . | Combination therapy (n = 28) . | |
| CLL/SLL | NR (13.9-NE) (n = 6) | — |
| WM | NR (NE-NE) (n = 1) | — |
| MCL | 9.7 (2.1-1 = 7.3) (n = 2) | — |
| FL | 7.6 (0.1-NE) (n = 5) | 11.3 (4.7-NE) (n = 4) |
| Nodal MZL | NR (NE-NE) (n = 1) | NR (NE-NE) (n = 1) |
| Splenic MZL | — | 6.1 (NE-NE) (n = 1) |
| DLBCL | NR (NE-NE) (n = 1) | NR (2.6-NE) (n = 6) |
| Transformed NHL | — | NR (NE-NE) (n = 1) |
| cHL | 8.9 (4.3-NE) (n = 5) | NR (2.6-NE) (n = 14) |
| PMBCL | — | — |
| NLP HL | — | 3.8 (NE-NE) (n = 1) |
NE, not estimable; NR, not reached.